Skip to main content
Medical information Clinical review pending

Genetic Testing

NDUFA13 Gene Hurthle Cell Thyroid Carcinoma Due to Germline NDUFA13 Mutation Genetic Test

Genetic test to identify mutations in the NDUFA13 gene associated with Hurthle cell thyroid carcinoma. Helps assess risk for individuals with a family history of this specific thyroid cancer.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for a blood draw. Follow any specific instructions provided by the laboratory or your doctor.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the NDUFA13 Gene Hurthle Cell Thyroid Carcinoma Due to Germline NDUFA13 Mutation Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a personal or family history of Hurthle cell thyroid carcinoma.
  • ✓Patients considering prophylactic thyroidectomy due to high familial risk.
  • ✓Family members of individuals known to have an NDUFA13 mutation.
  • ✓Assessment of genetic risk in individuals with multiple endocrine neoplasia syndromes.
  • ✓Research purposes related to thyroid cancer genetics.
02

In plain language

What this test helps you understand

Identifies germline mutations in the NDUFA13 gene, which are associated with an increased risk of developing Hurthle cell thyroid carcinoma. This information can aid in risk assessment and potentially guide surveillance or management strategies for individuals and families.
The NDUFA13 Gene Hurthle Cell Thyroid Carcinoma NGS Genetic DNA Test identifies mutations in the NDUFA13 gene linked to Hurthle cell thyroid carcinoma. This test uses Next-Generation Sequencing (NGS) technology to analyze your genetic makeup for specific mutations associated with this type of thyroid cancer. Understanding your genetic predisposition is important for early detection and proactive health management. This test analyzes a blood sample or extracted DNA to detect NDUFA13 mutations, which can indicate an increased risk of developing Hurthle cell thyroid carcinoma. Discuss the results with your healthcare provider to understand your personal risk and appropriate next steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for a blood draw. Follow any specific instructions provided by the laboratory or your doctor.
SampleBlood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) is used to analyze the NDUFA13 gene for specific mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only detects mutations within the NDUFA13 gene. It does not assess risk for other types of thyroid cancer or other genetic conditions. A negative result does not completely eliminate the risk of developing thyroid cancer. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Hurthle cell thyroid carcinoma is a specific type of thyroid cancer originating from the follicular cells of the thyroid gland. It is sometimes referred to as oxyphilic cell carcinoma.
This test is primarily recommended for individuals with a personal or family history of Hurthle cell thyroid carcinoma, or those with a known genetic predisposition.
A positive result indicates the presence of a mutation in the NDUFA13 gene associated with an increased risk of Hurthle cell thyroid carcinoma. Discuss the implications with your doctor.
A negative result means no NDUFA13 mutations associated with Hurthle cell thyroid carcinoma were detected in the sample. However, it does not rule out the possibility of developing thyroid cancer.
Results should be interpreted by a qualified healthcare professional, such as a genetic counselor or oncologist, considering your personal and family medical history.
Insurance coverage varies. Confirm coverage details with your insurance provider and the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp